

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> A61K 33/14, 31/70, 31/715 // (A61K 33/14, 33:10) (A61K 33/14, 33:06) (A61K 33/14, 33:00) (A61K 33/14, 31:70) (A61K 33/14, 31:70) (A61K 33/14, 31:715)	<b>A1</b>	<b>(11) International Publication Number:</b> WO 97/06810
		<b>(43) International Publication Date:</b> 27 February 1997 (27.02.97)
<b>(21) International Application Number:</b> PCT/CA96/00542 <b>(22) International Filing Date:</b> 9 August 1996 (09.08.96) <b>(30) Priority Data:</b> 2,155,910 11 August 1995 (11.08.95) CA <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/558,472 (CIP) Filed on 16 November 1995 (16.11.95) <b>(71)(72) Applicants and Inventors:</b> WU, George [CA/CA]; #3 Gerald Street, Willowdale, Ontario M2L 2M4 (CA). TAM, Paul, Y. [CA/CA]; #3 Gerald Street, Willowdale, Ontario M2L 2M4 (CA). FRENCH, Ian, W. [CA/CA]; #3 Gerald Street, Willowdale, Ontario M2L 2M4 (CA). <b>(74) Agent:</b> HUGHES, Etigson; Suite 200, 175 Commerce Valley Drive West, Thornhill, Ontario L3T 7P6 (CA).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> BIOCOMPATIBLE AQUEOUS SOLUTION FOR USE IN CONTINUOUS AMBULATORY PERITONEAL DIALYSIS		
<b>(57) Abstract</b>  A peritoneal dialysis solution comprising an effective amount of an acetylate or deacetylated amino sugar and/or combinations thereof.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**TITLE OF INVENTION**

Biocompatible Aqueous Solution For Use in Continuous Ambulatory Peritoneal Dialysis.

**SUMMARY OF THE INVENTION**

5 Continuous ambulatory peritoneal dialysis (CAPD) is used to treat end stage renal failure (ESRF) by introducing an osmotically active solution into the peritoneal cavity. Toxic waste products and excess fluid move from the blood into the dialysate solution by diffusion and ultrafiltration across the peritoneum. Osmotic ultrafiltration occurs as a result of the  
10 addition of hypertonic concentration of glucose to the dialysing solution. Due to the osmotic gradient between the blood and the CAPD solution the glucose draws water from the blood stream into the peritoneal cavity. The osmotic effect is transient and diminishes as the glucose is absorbed and/or metabolised.

15 In CAPD the dialysis solution is infused from collapsible plastic bags into the peritoneal cavity where it is retained for a period of time (referred to as the dwell time), after which it is drained and discarded. Generally, 3-5 treatments or exchanges of 1-3 litres each of CAPD solution are carried out daily, with an overnight dwell. The glucose concentration  
20 varies between 1.5 and 5% (w/v), with commercial CAPD solutions containing 1.5%, 2.5 or 4.5% glucose, with a high lactate content and various electrolytes which are present in more or less pH physiologic concentrations. CAPD patients also lose 5-10 grams of protein into the dialysate per day. Commercial CAPD solutions typically have an osmolality  
25 of 300-700 mOsm/L, preferably 350-450 mOsmol/L, as taught by Patent 5,011,826.

Although peritoneal dialysis has some advantages over hemodialysis, including a substantial cost saving, there are several potential complications to CAPD. These include protein loss through the  
30 relatively highly permeable peritoneal membrane, absorption and metabolism of the added glucose resulting in weight gain and hyperlipidemia, which is particularly problematic in diabetic patients, who have a high incidence of ESRF (Ong- Ajyooth, L., Transp Proc 26: 2077, 1994).

35 An average patient absorbs about 150 grams of glucose from the dialysate per day, which for many patients is an excessive source of carbohydrate and results in hyperinsulinemia and hypertriglyceridemia in non-diabetic patients, which contributes to atherosclerotic disease. This

series of events likely contributes to cardiovascular disease which is the most common cause of death among patients with ESRF.

Chronic exposure of the peritoneal membrane to the hypertonic and acidic CAPD solution (pH 5–6.2) can result in a loss of its function as an ultrafiltration membrane, leading to increased permeability of the peritoneal membrane and an increased rate of absorption of glucose from the dialysis solution and a loss of ultrafiltration capability. (Breborowicz et al *Advances in Peritoneal Dialysis* 8: 11, 1992 and Breborowicz et al *Nephron* 67: 350, 1994). Peritoneal biopsy samples from patients chronically dialysed with CAPD solutions show a typical epithelial reaction to irritation, mesothelial cell proliferation, as well as a decrease in the number of microvilli which normally line the mesothelial cell surface (Dobbie, J.W., Lloyd, J.K., Gall, C.A. In R. Khamma, K.D. et al Eds. *Advances in peritoneal dialysis*. Toronto. U of Toronto Press, 3, 1990: Friedlander, M. J *Lab Clin Med* 122: 639, 1993). A chronic inflammation of the peritoneum is also a consequence of chronic CAPD treatment, possibly related to the acidic nature of the CAPD solution (Lewis, S. & Holmes, C. *Periton Dial Int* 11: 14, 1991; Beelen, R.H.J. et al In Maher J.F., Winchester, J.F. Eds. *Frontiers in peritoneal dialysis*. New York: Field, Richj and Associates, 524, 1986; Bos, H.J. et al *Nephron* 59: 508, 1991), and which leads to healing (Weiczorowska, K. et al *Short Reports?*). Morphologic changes in the peritoneal structure also occur with chronic CAPD therapy, including fibrosis of the peritoneum (Chaimovitz, C., *Kidney Int* 45: 1226, 1994). Further, the use of the current relatively acidic and glucose hypertonic CAPD solutions results in a decrease in the function of peritoneal macrophages, again indicating a need for more physiologic and biocompatible CAPD solutions (deFijter, C.W.H. et al *Clin Nephrology* 39: 75, 1993).

As well, it has been shown that there is a loss of glycosoaminoglycans (GAG's) from the peritoneal membrane which results in a loss of filtration efficiency. It has been suggested that the loss of GAG's from the peritoneal membrane is a result of the increased production of free radicals by activated peritoneal leucocytes (Breborowicz, A. et al *Periton Dial Int* 11(Suppl): 35a, 1991) or because of a destructive action on interstitial tissue proteins (Fligiel, S.E.G. et al *Amer J Pathol* 115: 418, 1984). Supplementation of the dialysis fluid with the GAG chondroitin sulphate increases net ultrafiltration due to slower absorption of glucose and fluid from the peritoneal cavity (*Advances in Peritoneal Dialysis* 8: 11, 1992; *Nephron* 67: 346, 1994), possibly due to its ability to scavenge free radicals.

Other GAG's, such as heparin and dermatan have also been reported to scavenge free radicals (Hiebert, L., Liu, J.M., Semin Thromb Hemost 17: 42, 1991; Fracasso, A. et al J Amer Soc Neph 5: 75p, 1994). It has also been reported that hyaluronan (formerly known as hyaluronic acid), which also  
5 scavenges free radicals, protects the peritoneum from injury resulting from CAPD treatment (Wieczorowska, K. et al Perit. Dial. Int. 15:81, 1995). Supporting this is the finding that the dialysis fluid collected overnight has a higher concentration of hyaluronan than serum. For example, Yung, S. et al (Kidney Int 46: 527, 1994) found that hyaluronan levels increased in the  
10 dialysate from ESRF patients with or without peritonitis undergoing CAPD treatment, and that the peritoneal mesothelial cells were the likely source of the hylauronan. Hyaluronan is important in the regulation of cell proliferation during healing. Hyaluronan is a polymer of repeating molecules of N-acetylglucosamine and glucuronic acid; dermatan is  
15 composed of repeating units of N-acetylglucosamine and iduronic acid, and chondroitin is made up of glucuronic acid and N-acetylgalactosamine.

Breborowicz and Oreopulos have submitted a PCT patent application (EP-555087-A1) (priority 92US-830721) for the addition of free radical scavengers such as GAG's, including hyaluronic acid degradation  
20 products, to CAPD solutions during episodes of peritonitis to prevent against peritonitis-associated inflammatory reactions .

As noted above, N-acetylglucosamine (NAG) is a component of many GAG's. NAG is formed in almost all cells from glucose through a series of biochemical reactions which include the addition of the amine  
25 group from glutamine to glucose to form glucosamine, with N-acetylglucosamine being synthesized by way of acetyl-CoA. NAG then is converted to NAG-6-phosphate (which is converted into the epimer of NAG, N-acetyl-mannosamine 6-phosphate which is converted to N-acetylneuraminic acid 9-phosphate which is incorporated into sialic acids,  
30 gangliosides and glycoproteins), to NAG-1-phosphate (which is converted into UDP-N-acetylglucosamine (UDP-NAG) which is incorporated into GAG's such as chondroitins and glycoproteins). The UDP-NAG is also converted into GAG's such as hyaluronan and glycoproteins. Thus, NAG is the primary building block of many essential tissue components, whether  
35 they are comprised of NAG itself or related amino sugars such as N-acetylmannosamine and N-acetylgalactosamine.

It has been shown that orally administered glucosamine and N-acetylglucosamine (NAG) are absorbed and distributed throughout the

body rapidly, and incorporated into tissues and presumably into the GAG's of the body. These compounds are incorporated into the GAG's of the peritoneal membrane to prevent their depletion thus maintaining the integrity of the peritoneal membrane, and preventing or at least slowing down, the loss of membrane function as an ultrafiltration membrane. Thus, the replacement of part or all of the glucose in the presently available CAPD solutions with amino sugars, especially NAG, should provide a more biocompatible peritoneal dialysis solution, while providing the necessary osmotic effect required for the removal of excess water and also removal of waste substances by solvent drag from patients with ESRF undergoing CAPD treatment. Unlike glucose, which is utilized by almost all microorganisms as a source of energy, the amino sugars are relatively less metabolized and not as likely to support microbial growth thus reducing the tendency for patients undergoing chronic CAPD treatment to develop peritonitis, a common and serious adverse event associated with CAPD treatment. Because of the rapid removal; of NAG and other amino sugars from the systemic circulation by way of their incorporation into GAG's and various amino sugar containing tissue components the extent of metabolism into lipids is significantly reduced, thus reducing the risk of obesity, protein malnutrition, dyslipidemia and hypertriglyceridemia, hyperinsulinemia etc and the related adverse metabolic consequences.

In order for NAG and related amino sugars to be useful as osmotic agents in CAPD solutions they must have a high chemical purity similar to that which would be required for use in pharmaceutical products, which means a minimum purity of 98.5%. NAG which is of this purity can be manufactured by two methods. The first is the acid digestion of crude chitin, which is a linear polymer of repeating units of NAG obtained from crab and shrimp shells and other crustaceans, followed by isolation of the deacetylation of the individual NAG units to glucosamine. The glucosamine is isolated and crystallized to a high level of purity and then is reacylated using acetic anhydride to N-acetylglucosamine, which is precipitated and recrystallized from alcohol, such that its purity is greater than 98.5%. The second method of manufacturing NAG, and the preferred method, is to obtain NAG from dried crustacean shell or crude chitin by direct enzymatic digestion with an ensemble of enzymes including chitinase and chitobiase, which degrades the chitin polymer of NAG into disaccharide units of chitobiase and then into monomer units of NAG directly, without having to undergo any organic synthetic step. The NAG is recrystallized from alcohol

to a high degree of purity from ethanol. The enzymes required for this process are secreted into the growth media of various microorganisms, especially *Serratia marcescens*. Thus this method of manufacture not only provides NAG of a suitable purity for use in CAPD solutions but also permits

5 the relatively inexpensive production of NAG as the chitin or crustacean shells can be added directly to the cell-free growth medium from a culture of *S. marcescens* and the NAG readily isolated from the medium after a suitable reaction period. By varying the length of the enzymatic reaction time the production of polymers of varying units of NAG can be produced, which

10 can be further refined and isolated as specific molecular weight entities by way of separation using available chromatographic techniques, and which can be isolated, crystallized and further purified by recrystallization using methods familiar to those skilled in the methods of carbohydrate chemistry isolation and purification.

15 Patent 5, 011,826 teaches that CAPD solutions can use galactose alone or with glucose in varying ratios as the osmotically active agents, whereas Patent 4,879,280 teaches that disaccharides such as lactose, saccharose, cellobiose etc can be used similarly, both together with suitable electrolyte additives. As well patent 4,879,280 also shows the use

20 of trisaccharides, oligosaccharides and polysaccharides of a molecular weight less than 400,000 such as raffinose, starch, inulin, pectin, dextrans, hydroxy-ethyl starch (HES) and the like. For example, colloidal polymers of glucose of 4-250 glucose units long and with an weight average molecular weight of about 16,200 and a number average molecular weight of 5,800

25 has been clinically evaluated as component of a CAPD solution (Kidney Int 46: 496, 1994: US Patent 4,886,789). The osmolality of a 7.5% solution of this glucose polymer, called Icodextrin, was 282 mOsm/kg and had a pH of 5.3. However, neither the available scientific literature nor the available patents teach the use of polymers or oligimers of amino sugars such as N-

30 acetylglucosamine, N-acetylmannosamine or N-acetylgalactosamine and the like as the osmotically active components of CAPD solutions, which are the subject of the present invention.

Since the effectiveness of intraperitoneal dialysis depends on the presence of a hypertonic solution and osmolarity depends on the

35 number of molecules in solution, large molecules such as GAG's provide little of value to the osmotic effect of the CADP solution, and the dialysis solution must still contain excess glucose. Since N-acetylglucosamine and related amino sugars, as well as the other sugar and/or acidic

carbohydrates making up the GAG's have molecular weights similar to that of glucose, they would be osmotically active. Therefore, the inclusion of amino sugars, particularly N-acetylglucosamine, in a CAPD solution at concentrations ranging from 0.5 to 5%, with or without the presence of glucose, will provide an effective dialysis solution while being more biocompatible with the peritoneal membrane and thus preventing or slowing down the morphologic and functional deterioration of the peritoneal membrane and extending the time over which ESRF patients may effectively use CAPD treatment. This provides several benefits, including substantial cost saving to the health care system by reducing the need for expensive hemodialysis, a lower rate of peritoneal infection for patients receiving CAPD treatment, a lesser risk of cardiovascular disease due to a reduction in the lipid changes typical of use of currently available CAPD solutions, and a better quality of life for such patients.

Currently marketed CAPD solutions have the following typical composition per 100 mL of solution. Dextrose anhydrous 1.5, 2.5 or 4.25 plus Sodium Chloride 567 mg, Sodium lactate 392 mg, Calcium Chloride dihydrate 23.9 mg and Magnesium Chloride hexahydrate 15.2 mg. On a milliequivalence basis this represents 132 mEq Na/L, 3.24 mEq Ca/L, 1.5 mEq Mg/L, 101.75 mEq Cl/L and 36 mEq lactate/L. Alternately, the solution may contain malate, acetate or succinate in place of lactate. The solution typically has an osmotic pressure of 347 mOsmol/L.

The CAPD solution of this invention is intended to provide similar electrolyte levels as currently available CAPD solutions, except that the osmotically active carbohydrate composition is different, being composed of acetylated and deacetylated amino sugars including N-acetylglucosamine, glucosamine, N-acetylgalactosamine, galactosamine, N-acetylmannosamine, mannosamine each alone, or in combination at varying concentrations or with varying concentrations of glucose, or oligomers of N-acetylglucosamine, N-acetylmannosamine, N-galactosamine, galactosamine, mannosamine, and glucosamine such that they are comprised of at least 2 carbohydrate units and not more than 12 units. The composition may be a mixture of oligimers of varying amounts of each oligimer either alone or in combination with each other. As well the CAPD solutions of this patent may contain additional osmotically active agents in varying proportions to the acetylated and deacetylated amino sugars such as acidic carbohydrates which are also incorporated into the



tissue glycosaminoglycans (GAG's) such as glucuronic acid and iduronic acid.

In animal models of inflammatory bowel disease the colon becomes fibrotic, as does the peritoneum as a result of chronic intraperitoneal dialysis. The administration of a solution of NAG into the bowel of rats in which a chemically induced inflammatory bowel reaction with bowel wall thickening or fibrosis occurs, reduces in a dose dependent manner the fibrotic reaction to the inflammatory stimulus (Table 1). It is to be expected that in a similar manner NAG will prevent the development of fibrosis of the peritoneum in CAPD patients.

In addition to glucose CAPD solutions typically also contain a suitable number and quantity of electrolytes such that a more less physiologic solution is obtained. For example, lactate is included as a base substitute. Its absorption and metabolism will correct metabolic acidosis. Sodium is usually included at a concentration slightly lower to that found in plasma, or 132–137 mM/L, to promote sodium removal. Similarly, chloride is usually included in the CAPD solution at physiologic strengths of 100–110 mM/L.

The normal osmolarity of blood is approximately 280 mOsm/L, so that a CAPD solution must have a greater osmotic value than this if it to be effective as a dialysis solution, and preferably it should have an osmotic pressure of 300–700 mOsm/L, and more specifically 310–560, or in a more limited range, of 350 to 450 mOsm/L (from Patent 4,879,280).

**Table 1**

COLON FIBROSIS (AS MEASURED BY WEIGHT(gm) OF 8 cm OF COLON)	
INTRARECTAL ADMINISTRATION	MEAN $\pm$ SEM
Control (20 mg TNB* in 0.25 mL Ethanol)	2.301 $\pm$ 0.222
25 mg NAG/kg BWt 1 hr before TNB/EtOH	1.669 $\pm$ 0.142
50 mg NAG/kg BWt 1 hr before TNB/EtOH	1.339 $\pm$ 0.155
100 mg NAG/kg BWt 1 hr before TNB/EtOH	1.150 $\pm$ 0.068

\* TNB = trinitrobenzenesulfonic acid

In experiments in which rats were dialyzed for 4 hours with Hanks Balances salt solution with either glucose or N-acetylglucosamine added at a concentration of 75 mM or 214 mM, at a pH of 7.35 – 7.4. The

net ultrafiltration was calculated as the difference between the drained volume of dialysate after 4 hours dwell time in the peritoneal cavity and the infused volume (20 mL) of the dialysis fluid. As well, the concentration of urea and creatinine in the blood and the dialysis fluid were measured.

- 5 Permeability of the peritoneal membrane to urea and creatinine, expressed as the Mass Transfer Area Coefficient which was calculated according to the method of Krediet et al (Blood Purif 4: 194, 1986). The results, given in the Table below, clearly demonstrate that NAG results in a statistically significant increase in net ultrafiltration as well as peritoneal clearance of  
10 urea without increasing albumin or total protein loss into the dialysis fluid. In addition, the inclusion of NAG in the dialysate fluid stimulated the synthesis of hyaluronic acid, as shown by the more than 100% increase in amount of hyaluronic acid secreted in the dialysis fluid compared to the glucose treated rats. These in vivo experiments clearly demonstrate that NAG is a  
15 more effective osmotic agent than glucose when used for peritoneal dialysis.

	Glucose 75 mM (N=11)	NAG 75 mM (N=14)	Glucose 214 mM (N=11)	NAG 214 mM (N=13)
Net Ultrafiltration (mL/4 hrs)	-0.44 ± 2.0	-0.11 ± 1.6	11.45 ± 1.2	14.45 ± 1.6*
Mass Transfer Area Coef for Urea (mL/min)	0.344 ± 0.13	0.287 ± 0.13	0.212 ± 0.07	0.262 ± 0.15
Peritoneal Clearance of Urea (mL/min)	18.8 ± 2.2	18.4 ± 2.1	26.9 ± 2.0	30.0 ± 2.2**
Total Protein Dialysate/Serum Ratio (%)	4.3 ± 1.0	4.4 ± 0.6	2.8 ± 0.4	3.1 ± 0.5
Albumin Dilaysate/Serum Ratio (%)	4.0 ± 1.6	3.9 ± 1.2	1.6 ± 0.6	2.0 ± 0.9
Hyaluronic Acid in Dialysate Fluid (ug/L)	103 ± 21	226 ± 93*	91 ± 31	217 ± 96***

\* = statistically significant ('t'-test), p < 0.001

20 \*\* = statistically significant ('test'-test), p < 0.01

\*\*\* = statistically significant, P < 0.002

The stimulation of hyaluronic acid by N-acetylglucosamine was confirmed in tissue culture of human mesothelial cells.

25

As many changes can be made to the embodiments of the invention without departing from the scope of the invention, it is intended that all material

herein be interpreted as illustrative of the invention and not in a limiting sense.

**THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:**

1. A peritoneal dialysis solution which comprises a water solution with a pH compatible with the intended use of the product, with electrolytes, including sodium, chloride, calcium and magnesium of a suitable and compatible compositions and one or a combination of acetylated or deacetylated amino sugars, such as glucosamine, N-acetylglucosamine, galactosamine, N-acetylgalactosamine, mannosamine, N-acetylmannosamine as monomers or oligomers of 2 to 12 carbohydrate units alone or in combination with glucose and/or sodium lactate, malate, acetate, succinate and/or iduronic acid and/or glucuronic acid.
2. The solution of claim 1 in which the pH is in the range of 5 – 7.4 and the sodium concentration is present in the range of 115 – 140 mEquiv/L, calcium is present in the range of 0.6 mEquiv/L, chloride is present in the range of 100 – 145 mEquiv/L, magnesium is present in the range of 0 – 2 mEquiv/L, lactate, malate, acetate or succinate in the range of 30 – 45 mEquiv/L.
3. The solution of claim 1 in which the osmotically active agent is and amino sugar taken from the following group of compounds of glucosamine, N-acetylglucosamine, galactosamine, N-acetylgalactosamine, mannosamine or N-acetylmannosamine.
4. The solution of claim 3 in which the osmotically active agents are present at a concentration of 0.5 – 5.0 % (w/v).
5. The solution of claim 3 of which the osmotically active agents are present at the concentrations specified in claim 4 together with glucose at a concentration of 0.5 to 5.0% (w/v).
6. The solution of claim 1 in which the osmotically active agents are present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

7. A peritoneal dialysis solution comprising an effective amount of an acetate or deacetylated amino sugar and/or combinations thereof.

8. The peritoneal dialysis solution of claim 7 wherein the amino sugar is N-acetylglucosamine (NAG).

9. The peritoneal dialysis solution of claim 7 wherein the amino sugar is selected from glucosamine, N-acetylglucosamine, galactosamine, N-acetylgalactosamine, mannosamine, N-acetylmannosamine as monomers or oligomers of 2 to 12 carbohydrate units alone or in combination with glucose and/or sodium lactate, malate, acetate, succinate and/or iduronic acid and/or glucuronic acid.

10. The solution of claim 7 in which the pH is in the range of 5 – 7.4 and the sodium concentration is present in the range of 115 – 140 mEq/L, calcium is present in the range of 0.6 mEq/L, chloride is present in the range of 100 – 145 mEq/L, magnesium is present in the range of 0 – 2 mEq/L, lactate, malate, acetate or succinate in the range of 30 – 45 mEq/L.

11. The solution of claim 8 in which the pH is in the range of 5 – 7.4 and the sodium concentration is present in the range of 115 – 140 mEq/L, calcium is present in the range of 0.6 mEq/L, chloride is present in the range of 100 – 145 mEq/L, magnesium is present in the range of 0 – 2 mEq/L, lactate, malate, acetate or succinate in the range of 30 – 45 mEq/L.

12. The solution of claim 9 in which the pH is in the range of 5 – 7.4 and the sodium concentration is present in the range of 115 – 140 mEq/L, calcium is present in the range of 0.6 mEq/L, chloride is present in the range of 100 – 145 mEq/L, magnesium is present in the range of 0 – 2 mEq/L, lactate, malate, acetate or succinate in the range of 30 – 45 mEq/L.

13. The solution of claim 7 in which the amino sugar is taken from the following group of compounds of glucosamine, N-acetylglucosamine, galactosamine, N-acetylgalactosamine, mannosamine or N-acetylmannosamine.

14. The solution of claim 9 in which the amino sugar is taken from the following group of compounds of glucosamine, N-acetylglucosamine, galactosamine, N-acetylgalactosamine, mannosamine or N-acetylmannosamine.
15. The solution of claim 7 in which the amino sugar is present at a concentration of 0.5 – 5.0 % (w/v).
16. The solution of claim 8 in which the amino sugar is present at a concentration of 0.5 – 5.0 % (w/v).
17. The solution of claim 9 in which the amino sugar is present at a concentration of 0.5 – 5.0 % (w/v).
18. The solution of claim 10 in which the amino sugar is present at a concentration of 0.5 – 5.0 % (w/v).
19. The solution of claim 11 in which the amino sugar is present at a concentration of 0.5 – 5.0 % (w/v).
20. The solution of claim 12 in which the amino sugar is present at a concentration of 0.5 – 5.0 % (w/v).
21. The solution of claim 13 in which the amino sugar is present at a concentration of 0.5 – 5.0 % (w/v).
22. The solution of claim 14 in which the amino sugar is present at a concentration of 0.5 – 5.0 % (w/v).
23. The solution of claim 7 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.
24. The solution of claim 9 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino

sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

25. The solution of claim 10 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

26. The solution of claim 11 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

27. The solution of claim 12 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

28. The solution of claim 13 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

29. The solution of claim 14 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

30. The solution of claim 15 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

31. The solution of claim 16 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

32. The solution of claim 17 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

33. The solution of claim 18 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

34. The solution of claim 19 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

35. The solution of claim 20 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

36. The solution of claim 21 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.

37. The solution of claim 22 in which the amino sugar is present as monomers of the amino sugars specified or are oligomers of these amino sugars comprising 2 – 12 carbohydrate units, alone or together with glucose as detailed in claim 5.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 96/00542

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 A61K33/14 A61K31/70 A61K31/715 //(A61K33/14,33:10), (A61K33/14,33:06), (A61K33/14,33:00), (A61K33/14,31:70), (A61K33/14, 31:70), (A61K33/14,31:715)		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,91 08009 (NEPHRO-MEDICA PHARMAZEUTISCHE VERTRIEBS GMBH) 13 June 1991 see page 4, paragraph 2 - page 8, paragraph 1; examples 1-3 see page 9, paragraph 3 see page 16, paragraph 5-7 see page 17, paragraph 3 see page 18, paragraph 2; claims 1,3-7,9-11	1-37
A	WO,A,82 03773 (BAXTER TRAVENOL LABORATORIES INC.) 11 November 1982 see page 7, paragraph 2; claims 1,4,7,8 see page 8, paragraph 1 --- -/--	1,2,4,5, 7,10-12
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		
<input checked="" type="checkbox"/> Patent family members are listed in annex.		
<b>* Special categories of cited documents:</b> "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 10 January 1997		Date of mailing of the international search report 24. 01. 97
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016		Authorized officer Kanbier, D

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 96/00542

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 555 087 (BAXTER INTERNATIONAL INC.) 11 August 1993 cited in the application see column 10, line 9-10; claims 1-3,10-13 ---	1,3-7,9, 23-37
A	WO,A,83 00087 (BAXTER TRAVENOL LABORATORIES INC.) 20 January 1983 see page 2; claims 1-5,7 see page 5-6 ---	1,7
A	WO,A,93 00939 (LAEVOSAN GMBH) 21 January 1993 see page 3, paragraph 1; claims 1,5-9 -----	1,2,4,5, 7,10-12

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 96/00542

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9108009	13-06-91	DE-A- 3940052 DE-D- 59005355 EP-A- 0431465 ES-T- 2054200	06-06-91 19-05-94 12-06-91 01-08-94
WO-A-8203773	11-11-82	AU-A- 8392382 CA-A- 1168582 EP-A- 0077354	24-11-82 05-06-84 27-04-83
EP-A-555087	11-08-93	JP-A- 5345021	27-12-93
WO-A-8300087	20-01-83	CA-A- 1172563 EP-A- 0083360 US-A- 4761237	14-08-84 13-07-83 02-08-88
WO-A-9300939	21-01-93	DE-A- 4123001 AT-T- 130768 AU-B- 657785 AU-A- 2311892 CA-A- 2113164 CZ-A- 9400058 DE-D- 59204519 EP-A- 0593590 ES-T- 2081620 HU-A- 66136 JP-T- 7500024 SK-A- 2594	14-01-93 15-12-95 23-03-95 11-02-93 21-01-93 16-11-94 11-01-96 27-04-94 01-03-96 28-09-94 05-01-95 06-07-94